
This phase 2 clinical trial evaluated the efficacy and safety of retatrutide in treating obesity. Participants received subcutaneous retatrutide or placebo once weekly for 48 weeks. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events were gastrointestinal, with dose-dependent increases in heart rate observed. Overall, retatrutide demonstrated promising efficacy in reducing body weight in obese adults.
Like
Save
Share